Archived

Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)

Federal funding opportunity RFA-DA-25-057 from National Institutes of Health (Department of Health and Human Services).

Posted: June 27, 2024
Closed: November 27, 2024
Award ceiling: $500,000
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.279
Category: Education, Health
Archives: January 2, 2025

Program funding history

Awards made under Assistance Listing 93.279 across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $1.5B
FY2026 obligated: $1.5B
FY2027 (to date) obligated: $0
Awards in window: 4,922

Top recipients: Yale Univ, The Johns Hopkins University, University of California, San Diego, University of Pittsburgh - of the Commonwealth System of Higher Education, Regents of the University of Michigan

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is archived. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

Stimulant Use Disorder still does not have FDA- approved treatments. Neuromodulation, such as, for example, transcranial magnetic stimulation (TMC) has been successfully used for more than 10 years in major depressive disorder (MDD) where patients have failed one antidepressant and since 2018 it has been used for obsessive-compulsive disorder (OCD). Another example is transcranial direct current stimulation (tDCS) which is currently being developed for a range of mental and neurological conditions, and some of them have direct relevance for StUD vulnerable phenotype (cognitive dysfunction, compulsive, and impulsive traits). Other neuromodulation technologies potentially can also be applied to StUD. As not everyone who takes drugs becomes addicted, and while the StUD population's extreme heterogeneity represents a barrier to effective treatment development, there is a treatment gap that needs to be filled, especially for the high-risk vulnerable phenotype with low executive function and difficulties with response regulation - anxious-impulsive traits. Developing neuromodulation combined with behavioral treatment modalities (CBT, mindfulness-based approaches) that will help to maintain use decrease and prevent relapse would have tremendous value as a treatment option. Randomized controlled trials are needed to develop the treatment algorithms and to select the most efficacious one.

Who can apply

Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Small businesses
County governments
Public and State controlled institutions of higher education
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Independent school districts
State governments
For profit organizations other than small businesses
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
PAR-24-089 · National Institutes of Health · closes November 13, 2026
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
PAR-24-329 · National Institutes of Health · closes March 16, 2027
Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
PAR-26-001 · National Institutes of Health · closes May 7, 2027
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
PAR-25-100 · National Institutes of Health · closes May 7, 2027
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
PAR-25-446 · National Institutes of Health · closes August 21, 2028
Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)
PAR-24-268 · National Institutes of Health · closes January 27, 2027

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing